Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Cabozantinib Versus Sunitinib in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Brief Summary: The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma


Options:
A: Arm Label: Doublet; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Drug: Cabozantinib | Arm Label: Monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: Triplet; Type: EXPERIMENTAL; Interventions: Biological: Ipilimumab | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Doublet | Intervention Type: DRUG; Name: Cabozantinib; Assigned to Arm(s): Doublet | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Monotherapy | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Triplet
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Temsirolimus | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): B
C: Arm Label: Arm A (bevacizumab); Type: ACTIVE_COMPARATOR; Interventions: Biological: Bevacizumab, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study | Arm Label: Arm B (bevacizumab and temsirolimus); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Drug: Temsirolimus | Arm Label: Arm C (bevacizumab and sorafenib tosylate); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Drug: Sorafenib Tosylate | Arm Label: Arm D (sorafenib tosylate and temsirolimus); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Drug: Sorafenib Tosylate, Drug: Temsirolimus | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm A (bevacizumab), Arm B (bevacizumab and temsirolimus), Arm C (bevacizumab and sorafenib tosylate) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm A (bevacizumab), Arm B (bevacizumab and temsirolimus), Arm C (bevacizumab and sorafenib tosylate), Arm D (sorafenib tosylate and temsirolimus) | Intervention Type: OTHER; Name: Pharmacological Study; Assigned to Arm(s): Arm A (bevacizumab), Arm B (bevacizumab and temsirolimus), Arm C (bevacizumab and sorafenib tosylate), Arm D (sorafenib tosylate and temsirolimus) | Intervention Type: DRUG; Name: Sorafenib Tosylate; Assigned to Arm(s): Arm C (bevacizumab and sorafenib tosylate), Arm D (sorafenib tosylate and temsirolimus) | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): Arm B (bevacizumab and temsirolimus), Arm D (sorafenib tosylate and temsirolimus)
D: Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: Pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib

Answer: A